Emvododstat: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 187 patientsc19early.org

Emvododstat for COVID-19

Serious outcome risk
Emvododstat
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−132%
Mortality (1)−132%
Ventilation (1)−47%
RCTs (1)−132%
Late (1)−132%
00.511.5+
← Emvododstat
reduces riskIncreased
risk →
c19early.org
October 2026

Emvododstat COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Ngumah (DB RCT)−132%2.32 · 0.74–7.28death9/924/95FITE19
Late treatment−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.15
All studies−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1500.511.52+
Rotate screen for more detailsIncrease width for more details
← Emvododstat
reduces riskEmvododstat
increases risk →
c19early.org
October 2026

Emvododstat COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Ngumah (DB RCT)−132%2.32 · 0.74–7.289/924/95FITE19
Late treatment−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.15
All studies−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1500.511.52+
Rotate screen for more detailsIncrease width for more details
← Emvododstat
reduces riskEmvododstat
increases risk →
c19early.org
October 2026

Emvododstat COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Ngumah (DB RCT)−47%1.47 · 0.72–3.0016/9411/95FITE19
Late treatment−47%1.47 · 0.72–3.0016/9411/9547% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.29
All studies−47%1.47 · 0.72–3.0016/9411/9547% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+
Rotate screen for more detailsIncrease width for more details
← Emvododstat
reduces riskEmvododstat
increases risk →
c19early.org
October 2026

Emvododstat COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Ngumah (DB RCT)−132%2.32 · 0.74–7.28death9/924/95FITE19
Late treatment−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.15
All studies−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1500.511.52+
Rotate screen for more detailsIncrease width for more details
← Emvododstat
reduces riskEmvododstat
increases risk →
c19early.org
October 2026

Emvododstat COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Ngumah (DB RCT)−132%2.32 · 0.74–7.28death9/924/95FITE19
Late treatment−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.15
All studies−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1500.511.52+
Rotate screen for more detailsIncrease width for more details
← Emvododstat
reduces riskEmvododstat
increases risk →
c19early.org
October 2026

Emvododstat COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Ngumah (DB RCT)−132%2.32 · 0.74–7.289/924/95FITE19
Late treatment−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.15
All studies−132%2.32 · 0.74–7.289/924/95132% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1500.511.52+
Rotate screen for more detailsIncrease width for more details
← Emvododstat
reduces riskEmvododstat
increases risk →